
浏览全部资源
扫码关注微信
中南大学 湘雅医院,长沙 410008
聂闪闪,硕士,医师,从事中西医结合防治胃癌的基础与临床研究,E-mail:NSS085@csu.edu.cn
王东生,博士生导师,主任医师,从事中西医结合治疗肿瘤的临床与基础研究,E-mail:wdsh66@aliyun.com
收稿日期:2018-08-23,
网络出版日期:2019-01-04,
纸质出版日期:2019-05-05
移动端阅览
聂闪闪, 李洵, 赵玉航, 等. 加味四君子汤含药血清对胃癌细胞SGC-7901凋亡相关因子表达的影响[J]. 中国实验方剂学杂志, 2019,25(9):25-30.
Shan-shan NIE, Xun LI, Yu-hang ZHAO, et al. Effect of Modified Si Junzitang Drug Serum on Expression of Apoptosis-related Molecules of Gastric Cancer Cell SGC-7901[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(9): 25-30.
聂闪闪, 李洵, 赵玉航, 等. 加味四君子汤含药血清对胃癌细胞SGC-7901凋亡相关因子表达的影响[J]. 中国实验方剂学杂志, 2019,25(9):25-30. DOI: 10.13422/j.cnki.syfjx.20190824.
Shan-shan NIE, Xun LI, Yu-hang ZHAO, et al. Effect of Modified Si Junzitang Drug Serum on Expression of Apoptosis-related Molecules of Gastric Cancer Cell SGC-7901[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(9): 25-30. DOI: 10.13422/j.cnki.syfjx.20190824.
目的:
2
研究加味四君子汤含药血清对胃癌细胞SGC-7901凋亡相关因子表达的影响,进一步探讨其具体抗肿瘤作用机制。
方法:
2
40只SD大鼠随机分为加味四君子汤低、中、高剂量组(0.213,0.426,0.853 g·kg
-1
),空白组,每组10只,空白组给予等体积的生理盐水灌胃,各组连续灌胃10 d,末次给药1.5 h后,水合氯醛腹腔麻醉,心脏采血,分离血清,56 ℃灭菌,0.22 μm过滤,制备加味四君子汤高、中、低剂量组含药血清,各剂量组含药血清孵育胃癌细胞SGC-7901,运用流式细胞仪检测细胞早期和晚期凋亡情况,运用实时荧光定量聚合酶链式反应(Real-time PCR)技术检测肿瘤抑制基因p53,c-核蛋白类基因(c-Myc),半胱氨酸天冬氨酸蛋白酶-3(Caspase-3),凋亡相关基因B细胞淋巴瘤-2(Bcl-2) mRNA的表达,运用细胞免疫荧光技术检测p53,c-Myc
Caspase-3,Bcl-2蛋白的相对表达量情况。
结果:
2
与空白组比较,加味四君子汤含药血清高剂量组细胞凋亡比率显著升高(
P
<
0.01),且可使胃癌细胞SGC-7901早期+晚期凋亡率达到22.58%(
P
<
0.01)。Real-time PCR结果显示加味四君子汤中剂量组能显著促进Caspase-3 mRNA表达(
P
<
0.01),加味四君子汤高剂量组能显著上调p53及c-Myc mRNA表达量(
P
<
0.01),加味四君子汤高剂量组显著抑制Bcl-2 mRNA表达(
P
<
0.01)。免疫荧光结果显示加味加味四君子汤高剂量组能使c-Myc
Caspase-3,p53蛋白表达水平显著升高(
P
<
0.01),而Bcl-2蛋白表达水平显著降低(
P
<
0.05)。
结论:
2
加味四君子汤含药血清能抑制抗凋亡蛋白Bcl-2的表达,促进凋亡相关分子p53,c-Myc
Caspase-3的表达,发挥抗肿瘤作用。
Objective:
2
To explore the effect of modified Si Junzitang (MSJZT) drug serum on the expression of apoptosis-related molecules of gastric cancer cell SGC-7901 and further its anti-tumor mechanism.
Method:
2
A total of 40 SD rats were randomly divided into four groups: low-dose
middle-dose
high-dose MSJZT (0.213
0.426
0.853 g·kg
-1
) groups and normal group (
n
=10). The treatment groups were administrated through gastric perfusion
and the normal group was given the equivalent volume of normal saline for 10 days. 1.5 h after the last treatment
chloral hydrate peritoneal anesthesia was performed
blood was collected from heart
and different doses of serum were separated to prepare drug-containing serum of low-dose
middle-dose
high-dose MSJZT groups
in order to incubate SGC-7901 gastric cancer cell. Early and late apoptosis rates were detected with flow cytometry. Afterwards
the tumor suppressor gene p53
c-nucleoprotein gene (c-Myc)
cysteine-aspartic acid protease-3 (Caspase-3)
B-cell lymphoma-2 (Bcl-2) mRNA expressions were confirmed by fluorescence quantitative polymerase chain reaction (Real-time PCR). The protein expressions of p53
c-Myc
Caspase-3
Bcl-2 were detected by immunofluorescence.
Result:
2
Compared with the normal group
the high-dose MSJZT group could obviously increase the apoptosis rate to 22.58%(
P
<
0.01). The results of Real-time PCR showed that the middle-dose MSJZT group significantly promoted the mRNA expression of Caspase-3 (
P
<
0.01)
the medium-dose group significantly increased the mRNA expressions of p53 and c-Myc (
P
<
0.01)
and the high-dose group significantly inhibited the mRNA expression of Bcl-2 (
P
<
0.01). The immunofluorescence results showed that the high-dose MSJZT group could significantly increase the protein expressions of c-Myc
Caspase-3 and p53 (
P
<
0.01)
while the protein expression of Bcl-2 was significantly reduced (
P
<
0.05).
Conclusion:
2
MSJZT drug serum could exert an anti-tumor effect by inhibiting the expression of the anti-apoptotic protein Bcl-2
and promoting the expressions of pro-apoptotic-related molecules p53
c-Myc
Caspase-3.
Sano T , Coit D G , Kim H H , et al . Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association Staging Project [J]. Gastric Cancer , 2017 , 20 ( 2 ): 217 - 225 .
Mocellin S , Verdi D , Pooley K A , et al . Genetic variation and gastric cancer risk: a field synopsis and Meta-analysis [J]. Gut , 2015 , 64 ( 8 ): 1209 - 1219 .
Iveson T , Donehower R C , Davidenko I , et al . Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study [J]. Lancet Oncol , 2014 , 15 ( 9 ): 1007 - 1018 .
QI F , LI A , Inagaki Y , et al . Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer [J]. Biosci Trends , 2011 , 4 ( 6 ): 297 - 307 .
Pedersen B , Koktved D P , Nielsen L L . Living with side effects from cancer treatment-a challenge to target information [J]. Scand J Caring Sci , 2013 , 27 ( 3 ): 715 - 723 .
高启龙 , 朱亚楠 , 石变 , 等 . 青龙衣含药血清抑制胃癌SGC-7901细胞生长和诱导凋亡 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 13 ): 111 - 115 .
邹超 , 杨宇飞 . 四君子汤加减降低胃肠肿瘤患者术后复发转移的研究进展 [J]. 世界中医药 , 2015 , 10 ( 2 ): 297 - 300,303 .
张俊杰 . 四君子汤加味辅助治疗胃癌53例疗效观察 [J]. 国医论坛 , 2015 , 30 ( 6 ): 48 - 49 .
WU B , XUAN Z R . Progress in research on applying Sijunzi decoction in treating digestive malignant tumor [J]. Chin J Integr Med , 2007 , 13 ( 2 ): 156 - 159 .
JIE Y , HE W , YANG X , et al . Kruppel-like factor 4 acts as a potential therapeutic target of Sijunzi decoction for treatment of colorectal cancer [J]. Cancer Gene Ther , 2017 , 24 ( 9 ): 361 - 366 .
QIAN J , XIE H , GUO C X , et al . Si Jun Zi decoction demolition parties inhibit proliferation and induce apoptosis of human gastric cancer BGC823 side population [J]. Afr J Tradit Complement Altern Med , 2015 , 12 ( 6 ): 77 - 89 .
魏伟 , 吴希美 , 李元建 . 药理实验方法学 [M]. 4版 . 北京 : 人民卫生出版社 , 2010 : 70 - 73 .
陈皎皎 , 胡陵静 , 张国铎 , 等 . 四君子汤加味对肺癌化疗骨髓抑制的作用机制 [J]. 中国实验方剂学杂志 , 2018 , 24 ( 2 ): 180 - 185 .
Kim E , Moon A . Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells [J]. Oncol Let , 2015 , 9 ( 2 ): 897 - 902 .
张志敏 , 秦传蓉 , 章必成 , 等 . 小檗碱对肝癌HepG2细胞增殖和凋亡的调节作用 [J]. 医药导报 , 2018 , 37 ( 5 ): 512 - 518 .
刘倩 , 傅缨 , 资晓飞 , 等 . 小檗碱对高糖环境下HCCLM3细胞凋亡与自噬的影响 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 2 ): 68 - 73 .
丁大伟 , 章永红 . 以细胞凋亡通路为靶点的抗肿瘤中药研究进展 [J]. 中国老年学杂志 , 2018 , 38 ( 1 ): 239 - 241 .
白阳 , 叶健 , 王敬泽 . c-Myc功能及其下游靶点 [J]. 细胞生物学杂志 , 2007 , 29 ( 2 ): 191 - 196 .
徐媛辉 , 唐丹凤 , 潘小玲 , 等 . 原癌基因c-Myc的生物学功能及在卵泡发育中的作用 [J]. 南昌大学学报:医学版 , 2010 , 50 ( 11 ): 97 - 101 .
李雪莉 , 郝远瑞 , 邹建湘 , 等 . C-myc, Bcl-2与胃癌生物学行为和细胞凋亡 [J]. 新消化病学杂志 , 1997 , 5 ( 12 ): 28 - 29 .
Um H D . Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species [J]. Oncotarget , 2016 , 7 ( 5 ): 5193 - 5203 .
陈伟 , 马磊 , 杨立山 . 甘草次酸对哮喘大鼠气道重塑及肺组织Casepase-3、Bax、Bcl-2表达的影响 [J]. 中药药理与临床 , 2016 , 32 ( 4 ): 16 - 19 .
于曼 , 胡图强 . 姜黄素通过P53通路诱导人舌鳞癌细胞的凋亡 [J]. 湖北医药学院学报 , 2018 , 37 ( 2 ): 132 - 135 .
0
浏览量
13
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621